Abstracts tagged "autoimmune diseases"

Abstract Number: 0411 • ACR Convergence 2021
Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial
Takemichi Fukasawa¹, Ayumi Yoshizaki², Satoshi Ebata² and Shinichi Sato², ¹Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: The exact role of interleukin-17 in systemic sclerosis (SSc) has not been established. This trial assessed the pharmacokinetics (PK), safety, and efficacy of multiple…
Abstract Number: 0559 • ACR Convergence 2021
Targeting NNMT as a Novel Metabolic Approach to Treat Systemic Sclerosis
M.Asif Amin¹, Bo Shi², Pei-Suen Tsou¹, Swarna Bale¹, Phillip Campbell¹, Mikel Gurrea-Rubio¹, Mark Eckert³, Ernst Lengyel³, Johann Gudjonsson⁴ and Varga John¹, ¹University of Michigan, Ann Arbor, MI, ²Nothwestern university, Chicago, IL, ³University of chicago, Chicago, IL, ⁴Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Fibrosis, the hallmark of systemic sclerosis (SSc), is associated with metabolic and epigenetic alterations that are incompletely characterized. Our laboratory had previously implicated dysregulated…
Abstract Number: 0966 • ACR Convergence 2021
Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
Garett Dunlap¹, Allison Billi², Feiyang Ma³, Johann Gudjonsson², J. Michelle Kahlenberg⁴ and Deepak Rao⁵, ¹Harvard University, Somerville, MA, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³University of California Los Angeles, Los Angelas, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Cutaneous lupus erythematosus (CLE) is commonly present in patients with systemic lupus erythematosus (SLE), but can also exist as an isolated manifestation without further…
Abstract Number: 1089 • ACR Convergence 2021
Clinical Associations of Anti-Ro52 Antibodies in Patients with Systemic Autoimmune Rheumatic Diseases
Diana Prieto-Peña¹, Belén Atienza-Mateo², Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Anti-SSA/Ro antibodies (Abs) can target Ro60 and Ro52 antigens. The presence of anti-Ro60 Abs has been widely described in patients with systemic autoimmune rheumatic…
Abstract Number: 1454 • ACR Convergence 2021
RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis
Allan Klein¹, Massimo Imazio², Paul Cremer¹, Antonio Brucato³, Antonio Abbate⁴, Fang Fang⁵, Antonella Insalaco⁶, Martin LeWinter⁷, Basil S. Lewis⁸, David Lin⁹, Sushil A. Luis¹⁰, Stephen J. Nicholls¹¹, Arian Pano⁵, Alistair Wheeler¹², Liangxing Zou⁵ and John F Paolini⁵, ¹Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, ²University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy, ³Department of Biomedical and Clinical Science, University of Milano, Fatebenefratelli Hospital, Milan, Italy, ⁴VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁵Kiniksa Pharmaceuticals Corp., Lexington, MA, ⁶Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, ⁷Cardiology Unit, The University of Vermont Medical Center, The University of Vermont, Burlington, VT, ⁸Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel, ⁹Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ¹⁰Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, NY, ¹¹MonashHeart, Department of Cardiology, Monash University, Clayton, Australia, ¹²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda
Background/Purpose: Recurrent pericarditis (RP) is an autoinflammatory disease with no FDA-approved therapies. RHAPSODY, a global Phase 3 study, evaluated rilonacept, a once-weekly IL-1α/IL-1β trap, in…
Abstract Number: 1554 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
Valeria Valerio¹, Emmanouil Rampakakis², Marie Hudson³, Sasha Bernatsky³, Elizabeth M. Hazel³ and Ines Colmegna⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²JSS Medical Research, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Vaccination is fundamental to reduce COVID-19 risk and its complications. Vaccine hesitancy is a threat to COVID-19 vaccination uptake. We assessed the frequency of…
Abstract Number: 1740 • ACR Convergence 2021
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Kenneth Kalunian³, Konstantina Psachoulia⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁴, ¹Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ²Monash University, Melbourne, Australia, ³University of California, La Jolla, CA, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 We investigated…
Abstract Number: PP10 • ACR Convergence 2021
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Noriko Okochi¹, Eiji Oishi² and Mika Ishiguro¹, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan
Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
Abstract Number: 0085 • ACR Convergence 2021
Association of CD20 Inhibitor Use with Severe COVID-19 Outcomes
Naomi Patel¹, Kristin D'Silva¹, Tiffany Hsu², Michael Di Iorio³, Xiaoqing Fu¹, Claire Cook⁴, Lauren Prisco⁵, Lily Martin⁶, Kathleen Vanni⁶, Alessandra Zaccardelli⁶, Yuqing Zhang⁷, Jeffrey Sparks⁶ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Pound Ridge, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Quincy, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with immune-mediated diseases have similar risk of severe COVID-19 versus the general population but CD20 inhibitor users may be at increased risk of…
Abstract Number: 0186 • ACR Convergence 2021
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases: Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Mueller⁶, Carl Coeck⁷, Klaus B Rohr⁸ and Wim A Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, UK, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁷SCS Boehringer Ingelheim Comm.V., Brussels, Belgium, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis (IPF), nintedanib reduced the rate of decline in forced…
Abstract Number: 0432 • ACR Convergence 2021
Anti-IL5 Therapy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Longitudinal Follow-up Study ≥ 24months
Allyson Egan¹, Pasupathy Sivasothy², Lisa Willcocks², Rachel Jones², Marcos Martinez Del Pero³ and David R.W. Jayne⁴, ¹Vasculitis and Lupus Centre, Cambridge University Hospital, University of Cambridge, London, United Kingdom, ²Vasculitis and Lupus Centre, Department of Medicine, Cambridge University Hospital, Cambridge, United Kingdom, ³Vasculitis and Lupus Centre, Cambridge University Hospital, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0617 • ACR Convergence 2021
Concerns and Beliefs About COVID-19 Vaccination Among Racial and Ethnic Minority Patients with Rheumatic Disease
Maria I. Danila, Lesley Jackson, Amy Mudano, Giovanna Rosas, Jeanne Merchant, Jeffrey Foster and Kenneth Saag, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Alabama lags behind many other states in COVID-19 vaccination uptake and racial/ethnic minority groups face COVID-19 vaccine access disparities. Moreover, lack of vaccination access…
Abstract Number: 0968 • ACR Convergence 2021
Granzyme K+ CD8 T Cells Form the Core Population of Inflamed Human Tissue-associated CD8 T Cells
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas¹, Gerald Watts¹, Garett Dunlap³, Heather Faust¹, Karishma Rupani¹, Joseph Mears¹, Deepak Rao¹, Runci Wang⁴, Gregory Keras¹, Nida Meednu⁵, Jonathan Coblyn¹, Elena Massarotti¹, Derrick Todd¹, Andrew McDavid⁶, Jennifer Anolik⁵, Accelerating Medicines Partnership AMP: RA/SLE Network⁷, Kevin Wei¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard University, Somerville, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵University of Rochester Medical center, Rochester, NY, ⁶University of Rochester, Rochester, NY, ⁷NIH/FNIH, Bethesda, MD, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: T cell-derived pro-inflammatory cytokines are a major driver of rheumatoid arthritis (RA) pathogenesis. While CD4 T cells have traditionally been assumed to be the…
Abstract Number: 1090 • ACR Convergence 2021
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Diana Prieto-Peña¹, Belén Atienza-Mateo², Miguel Ángel gonzalez-Gay³, Ricardo Blanco⁴ and Marcos Lopez-Hoyos⁵, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain
Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…
Abstract Number: 1459 • ACR Convergence 2021
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials
Eric Morand¹, Gabriel Abreu², Richard Furie³ and Raj Tummala⁴, ¹Monash University, Melbourne, Australia, ²BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a treat-to-target (T2T) endpoint for SLE, is prospectively validated as protective from flares and damage accrual.1 LLDAS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].